BioCryst (BCRX) Jumps Higher After Canceling Conference Appearance
More News related to BCRX
- Positives Seen On BioCryst (BCRX) After Peramivir Granted Priority Review In Japan
- BioCryst Pharma (BCRX) Priced 5M Common Offering at $9.75/Share
- BioCryst Announces Pricing of Public Offering of Common Stock
- Momentum Mover BioCryst (BCRX) Down On Stock Offering
- BioCryst Pharma (BCRX) Files 5M Common Stock Shelf
More News related to FDA
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- A Rough Week for AT&T (T)
- More Thoughts On Apple's (AAPL) Quick Sell-Off Yesterday
- Tiger's Days as Advertising King are Over
- Jarden (JAH) Offers Variety of Products and Good Earnings Potential -Cramer
Shares of BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) are flying higher this afternoon after updating on its website that they cancelled today's appearance at an Oppenheimer conference "due to recent developments". Speculators are betting on a takeover or major partnership. Shares are up 7.6% on heavier-than-normal volume.
BioCryst recently received emergency use authorization for the investigational anti-viral drug intravenous peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.
Related Categories
FDAMomentum Movers
Rumors
Trader Talk
Stocks Mentioned
-0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
